Abstract 2108P
Background
Vitamin B12 impairment is common in cancer patients due to several factors, namely gastrointestinal (GI) surgery, malnutrition, liver metastases, and chemotherapy. Data regarding their prevalence and significance in this setting, as well as the impact on the overall prognosis, are lacking.
Methods
We retrospectively enrolled patients hospitalized for various cancer-related conditions at our Medical Oncology ward (2017-2022). Plasma B12 levels were stratified as Very Low (VL <200 pg/ml), Low (L 200-300 pg/ml), Normal (N 300-813 pg/ml) or High (H >813 pg/ml). We collected demographic and clinical data, including BMI, Cumulative Illness Rating Scale, nutritional status, ECOG PS, primary cancer site, disease stage, liver involvement and function tests, GI surgery. Univariate and multivariate statistical tests identified variables statistically associated to vitamin B12 (p<0.05).
Results
We enrolled 788 patients (F/M: 1.05, median age: 72, IQR: 62-78 y), VL B12 levels were found in 14.09% cases, L in 19.42%, N in 49.37% and H in 17.13%. At univariate analysis, B12 distribution was significantly different between genders, with females being characterized by higher median values compared to males. Vitamin B12 distribution increased significantly as function of ECOG PS levels. Breast cancer patients were characterized by the highest median B12 value while colorectal cancer patients by the lowest. B12 was also significantly higher in advanced compared to early-stage patients as well as in those who had liver failure. The correlation between B12 and age, albumin, prealbumin, total protein and folates was statistically significant but negligible (|r|<0.3). Multivariate analysis showed that the probability of H vs VL B12 levels was increased in patients with hypoproteinemia, hypoprealbuminemia and ECOG PS≥2, and decreased in those with colorectal and gastric cancer
Conclusions
To our knowledge, this is the first study investigating B12 levels in a wide and well clinically-characterized group of cancer patients; our data suggest that increased B12 is associated to an impaired clinical status, while in early stage patients, especially the elderly, B12 deficiency is of concern and may negatively impact the overall outcomes.
Clinical trial identification
#2734CE, released on the 31/01/2023.
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Pavia - Istituti Clinici Scientifici Maugeri.
Funding
Has not received any funding.
Disclosure
A. Malovini: Financial Interests, Personal, Stocks/Shares: Biomeris S.R.L. L.D. Locati: Financial Interests, Institutional, Speaker, Consultant, Advisor: Lilly, Eisai, MSD, Ipsen, Bayer, Roche, Gentili SrL. All other authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06